Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.54 |
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | ESRRG | P62508 | 1/20 | 0.36 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13078234 | 0.84 | PPARG (0.47) | CYP4A11PPARACYP4F2EPHX2HPGD | |
| SCHEMBL7625577 | 0.82 | PPARA (0.73) | CYP4A11PPARACYP4F2LTA4HEPHX2 | |
| SCHEMBL3511047 | 0.80 | HTT (0.53) | EPHX2NPC1RAB9A | |
| SCHEMBL13994548 | 0.80 | KMT2A (0.50) | HPGD | |
| SCHEMBL2716903 | 0.80 | CYP3A4 (0.44) | — | |
| SCHEMBL10349973 | 0.79 | MEN1 (0.49) | NPC1HPGDRAB9A | |
| SCHEMBL24172240 | 0.78 | CYP4A11 (0.57) | CYP4A11PPARACYP4F2LTA4HEPHX2 | |
| SCHEMBL13042125 | 0.75 | ACACB (0.39) | — | |
| SCHEMBL2983443 | 0.75 | CYP4F2 (0.45) | CYP4A11PPARACYP4F2CA2 | |
| SCHEMBL2983440 | 0.75 | CYP4F2 (0.45) | CYP4A11PPARACYP4F2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286144-A1 | HETEROARYL DERIVATIVES | TAKAHASHI YOKO | 2010-11-11 | — | — | US | disclosed |
| US-7781479-B2 | Heteroaryl derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1837329-A1 | NOVEL HETEROARYL DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286144-A1 | HETEROARYL DERIVATIVES | GPR119, SLC2A1, SLC2A4 | CYP4A11 46/4885PPARA 489/4885CYP4F2 349/4885 |
| US-20080167306-A1 | Novel Heteroaryl Derivative | GPR119, SLC2A4, SLC5A2 | CYP4A11 37/4885PPARA 561/4885CYP4F2 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.